Contrave, the anti-obesity pill from Orexigen (NASDAQ:OREX) saw sales increase by 10% this past week. Contrave sold just above 8,400 scripts for its best week to date. The sales data, tabulated by IMS Health, shows Contrave gaining in market share this week after we had seen flat scripts for about three weeks. For Orexigen investors, the numbers this week are welcomed relief after seeing the impressive launch flatten out in response to competitor Beliviq from Arena (NASDAQ:ARNA) being offered at a new lower price. Read more